Groupe IRD PEG
Delisted
The PEG Ratio (Price/Earnings-to-Growth) of Groupe IRD (IRD.PA) as of Aug 1, 2026 is 0.37. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.90 — a change of -58.77% (lower).
Get this data via API
Financial Data API
PEG
0.37
YoY
-58.77%
Last updated:
PEG Ratio (Price/Earnings-to-Growth) of Groupe IRD is 2026 0.37 . PEG Ratio (Price/Earnings-to-Growth) of Groupe IRD was 2025 0.90 . It decreases by -58.77% lower compared to the previous year.
Access this data via the Eulerpool API
Groupe IRD Stock analysis
What does Groupe IRD do? Groupe IRD SA is an internationally active company specializing in the development and production of medical diagnostics and food tests. The company's history dates back over 70 years, when it was founded by Dr. Paul Dettwiler in 1949.
Since then, the company has grown from a small laboratory to a world-leading provider of tests for medicine and food safety. Groupe IRD SA's business model is based on innovative technologies, product quality, and customer orientation.
The company has various business divisions that focus on the different needs of its customers. The diagnostic division is involved in the manufacture and distribution of medical tests for laboratory diagnostics, particularly for infectious diseases such as HIV, hepatitis, or tuberculosis. IRD offers a comprehensive range of tests, ranging from simple rapid tests to advanced diagnostic platforms.
Another important area of Groupe IRD SA is food safety. The company develops and produces fast, reliable, and precise tests to examine a variety of foods for potential contaminants such as pesticides, antibiotics, or allergens. These tests are used in both food production facilities and by authorities.
IRD is also a major manufacturer of test kits for animal health. These include tests for the early detection of infectious diseases such as brucellosis or paratuberculosis. Veterinarians and farmers use these tests to protect their herds from disease outbreaks.
In addition to the three core areas, IRD also operates an extensive service program that provides assistance to its customers in setting up laboratories and conducting training in test handling. The company strives to work closely with its customers to understand their needs and offer them the best possible products and services.
Innovation and research play a major role in the corporate philosophy of Groupe IRD SA. The company continuously invests in the development of new products and technologies and is always seeking to improve its existing products. IRD also places great importance on sustainable and environmentally friendly production, and strives to minimize its ecological footprint.
Overall, Groupe IRD SA has become an internationally active company with nearly 200 employees and operates in over 100 countries worldwide. The company has earned an excellent reputation as a reliable manufacturer of diagnostic and food test kits and is constantly striving to improve its products and satisfy its customers. Groupe IRD is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Groupe IRD stock
PEG Ratio (Price/Earnings-to-Growth) of Groupe IRD is 0.37 in 2026.
Access this data via the Eulerpool API
Valuation — Groupe IRD
All Key Metrics — Groupe IRD
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth